使用敲除细胞株进行验证RabMAb

Anti-PACT (PKR activating protein) / PRKRA抗体[EPR3224] (ab75749)

概述

  • 产品名称Anti-PACT (PKR activating protein) / PRKRA抗体[EPR3224]
    参阅全部 PACT (PKR activating protein) / PRKRA 一抗
  • 描述
    兔单克隆抗体[EPR3224] to PACT (PKR activating protein) / PRKRA
  • 经测试应用适用于: WB, IHC-Pmore details
    不适用于: Flow Cyt,ICC or IP
  • 种属反应性
    与反应: Mouse, Rat, Human
  • 免疫原

    Synthetic peptide corresponding to residues from the C terminal of human PACT (PKR activating protein)/ PRKRA

  • 阳性对照
    • K562, Jurkat and HepG2 cell lysates. Human brain tissue.
  • 常规说明

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

性能

应用

Our Abpromise guarantee covers the use of ab75749 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB
IHC-P
  • 应用说明IHC-P: 1/100 - 1/250. Perform heat mediated antigen retrieval using 0.01M Sodium Citrate Buffer, pH 6.0 before commencing with IHC staining protocol.
    WB: 1/1000 - 1/5000. Detects a band of approximately 34 kDa (predicted molecular weight: 34 kDa).

    Is unsuitable for Flow Cyt, ICC or IP.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • 靶标

    • 功能Activates EIF2AK2/PKR in the absence of double stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1.
    • 疾病相关Defects in PRKRA are the cause of dystonia type 16 (DYT16) [MIM:612067]. DYT16 is an early-onset dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT16 patients have progressive, generalized dystonia with axial muscle involvement, oro-mandibular (sardonic smile) and laryngeal dystonia and, in some cases, parkinsonian features.
    • 序列相似性Belongs to the PRKRA family.
      Contains 3 DRBM (double-stranded RNA-binding) domains.
    • 结构域Self-association may occur via interactions between DRBM domains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 or DRBM 3/DRBM3.
    • 翻译后修饰Phosphorylated at Ser-246 in unstressed cells and at Ser-287 in stressed cells. Phosphorylation at Ser-246 appears to be a prerequisite for subsequent phosphorylation at Ser-287. Phosphorylation at Ser-246 and Ser-287 are necessary for activation of EIF2AK2/PKR under conditions of stress.
    • 细胞定位Cytoplasm > perinuclear region.
    • Information by UniProt
    • 数据库链接
    • 别名
      • DYT16 antibody
      • HSD14 antibody
      • Interferon inducible double stranded RNA dependent protein kinase activator A antibody
      • interferon-inducible double stranded RNA-dependent activator antibody
      • Interferon-inducible double stranded RNA-dependent protein kinase activator A antibody
      • PACT antibody
      • PKR associated protein X antibody
      • PKR associating protein X antibody
      • PKR-associated protein X antibody
      • PKR-associating protein X antibody
      • PRKRA antibody
      • PRKRA_HUMAN antibody
      • Protein activator of the interferon induced protein kinase antibody
      • Protein activator of the interferon-induced protein kinase antibody
      • Protein kinase antibody
      • Protein kinase interferon inducible double stranded RNA dependent activator antibody
      • RAX antibody
      see all

    Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] 图像



    • Predicted band size : 34 kDa

      Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: PACT (PKR activating protein)/PRKRA knockout HAP1 cell lysate (20 µg)
      Lane 3: K562 cell lysate (20 µg)
      Lane 4: HepG2 cell lysate (20 µg)
      Lanes 1 - 4: Merged signal (red and green). Green - ab75749 observed at 36 kDa. Red - loading control, ab18058, observed at 124 kDa.
      ab75749 was shown to specifically react with PACT (PKR activating protein)/PRKRA when PACT (PKR activating protein)/PRKRA knockout samples were used. Wild-type and PACT (PKR activating protein)/PRKRA knockout samples were subjected to SDS-PAGE. ab75749 and ab18058 (loading control to Vinculin) were diluted at 1/1000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

    • All lanes : Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] (ab75749) at 1/1000 dilution

      Lane 1 : K562 cell lysate
      Lane 2 : Jurkat cell lysate
      Lane 3 : HepG2 cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 34 kDa
      Observed band size : 34 kDa
    • ab75749 at 1/100 dilution staining PACT (PKR activating protein) / PRKRA in paraffin-embedded human brain tissue.

    Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] (ab75749)参考文献

    This product has been referenced in:
    • Gross TJ  et al. A microRNA processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. J Biol Chem 289:12823-34 (2014). WB ; Human . Read more (PubMed: 24668803) »
    • Caramuta S  et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J 3:e152 (2013). WB ; Human . Read more (PubMed: 24121164) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab75749.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"